The DOI matches its Crossref record; 26 of the 30 references it cites were found in a registry or an index.
Lipoprotein Glomerulopathy: Glomerular Lipoprotein Thrombi in a Patient With Hyperlipoproteinemia
Abstract
An unusual nephropathy presumably induced by abnormal lipid metabolism is described in a 57-year-old woman who presented with proteinuria and edema. Histology at renal biopsy was characterized by marked dilatation of capillary lumina. Sudan staining and electron microscopy demonstrated lipid droplets occupying the capillary lumina. The patient had no particular clinical symptoms of lipidosis, but hyperlipoproteinemia similar to type III was suggested by lipid profiles. The nephropathy is thought to be an inherited disorder because proteinuria was detected in her sisters and similar renal histology and lipid profile were observed in one of her sisters. This is believed to be the first detailed report of glomerular lipoprotein thrombi.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lipoprotein glomerulopathy (LPG) was initially reported in Japan [2] and later known to be associated with various heterozygous ApoE variants, e.g., ApoE Sendai [3] and ApoE Kyoto [4].”
From Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2 (2018) · cites this paper as [2]
In the citing paper
“Diagnosis of LPG relies primarily on renal pathology, with typical lipoprotein thrombosis within dilated glomerular capillary loops.”
From A case report of youth-onset lipoprotein glomerulopathy with APOE Chicago mutation (2024) · cites this paper as [1]
In the citing paper
“Lipoprotein glomerulopathy (LPG) is an inherited glomerular disease caused by mutations in the APOE gene, usually with clinical manifestations of dysregulated lipid metabolism, proteinuria, and renal insufficiency.”
From A case report of youth-onset lipoprotein glomerulopathy with APOE Chicago mutation (2024) · cites this paper as [1]
In the citing paper
“The first 2 cases of LPG were reported by Japanese scholar Saito et al. in the same family in 1989 [1].”
From A case report of youth-onset lipoprotein glomerulopathy with APOE Chicago mutation (2024) · cites this paper as [1]
In the citing paper
“Massive lipoprotein thrombi in the lumens of dilated glomerular capillaries are the typical pathological manifestation of LPG3).”
From The Novel Apolipoprotein E Mutation ApoE Chengdu (c.518T＞C, p.L173P) in a Chinese Patient with Lipoprotein Glomerulopathy (2018) · cites this paper as [3]
In the citing paper
“In contrast to apoE2 homozygote glomerulopathy, LPG is characterized by dilation of glomerular capillaries with lipoprotein thrombi showing lamellar formation, directly inducing glomerular damage without inducing foamy changes68).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [68]
In the citing paper
“LPG is a rare renal disease first reported in Japan in 1989 68).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [68]
In the citing paper
“LPG was initially identified as a glomerular disease associated with type III HLP68).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [68]
In the citing paper
“Histological features are the most important evidence for the diagnosis of LPG [2].”
From A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports (2022) · cites this paper as [2]
In the citing paper
“Immunofluorescence microscopy shows positive staining of ApoE and ApoB in lumen thrombotic substances.”
From A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports (2022) · cites this paper as [2]
In the citing paper
“Nearly half of mutations occurred in the LDL-receptor binding site (LRBS), such as ApoE Sendai (Arg145Pro) [2], ApoE Chicago (Arg147Cys) [16], ApoE Guangzhou (Arg150Pro)[17], ApoE Modena (Arg 150Cys) [11], ApoE Okayama (Arg150Gly) [18], ApoE Tokyo (Del 141-143) [19], and ApoE Maebasi (Del 142-144). These mutations might result in reduced binding capacity of ApoE protein to LDL receptor.”
From A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports (2022) · cites this paper as [2]
In the citing paper
“Under light microscopy, the capillary lumen is typically highly dilated and filled with lightly stained reticular material.”
From A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports (2022) · cites this paper as [2]
In the citing paper
“Lipoprotein glomerulopathy (LPG) is a rare inherited disease characterized by histopathological features of lipoprotein thrombi in dilated glomerular capillaries and type III like hyperlipoproteinemia with heterozygous mutation of the apolipoprotein (apo) E gene.”
From A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I (2018) · cites this paper as [1]
In the citing paper
“Lipoprotein glomerulopathy (LPG) is a condition first described in Japan in 1989.1”
From Lipoprotein Glomerulopathy, First Case Report from Canada (2022) · cites this paper as [1]
Citations
Cites
Hatch, F. T., & Lees, R. S. (1968) · Advances in lipid research · doi:10.1016/b978-1-4831-9942-9.50008-5 · Cited by 1,235
Renal Disease. Classification and Atlas of Glomerular Diseases.
(1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-5-801_2 · Cited by 675
Apolipoprotein E polymorphism in health and disease
Utermann, G. (1987) · American Heart Journal · doi:10.1016/0002-8703(87)90610-7 · Cited by 389
LACTIC ACIDOSIS AND HYPERLACTATÆMIA
Cohen, R. D., Woods, H. F., & Alberti, K. G. M. M. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91784-x · Cited by 222
Type III Hyperlipoproteinemia: An Analysis of Two Contemporary Definitions
Fredrickson, D. S., MORGANROTH, J., & LEVY, R. I. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-2-150 · Cited by 177
Bouthillier, D., Sing, C. F., & Davignon, J. (1983) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37920-7 · Cited by 176
The clinical spectrum of renal cholesterol embolization
Smith, M. C. F., Ghose, M., & Henry, A. R. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90290-4 · Cited by 147
Hazzard, W. R., Porte, D., & Bierman, E. L. (1972) · Metabolism · doi:10.1016/0026-0495(72)90031-5 · Cited by 134
The Progressive nature of renal disease
Mitch, W. E. (1986) · Churchill Livingstone eBooks · Cited by 131
Grond, J., Weening, J. J., & Elema, J. D. (1984) · PubMed · Cited by 107
Research works printed but not linked: 2
- Hatch, 1986, Practical methods for plasma lipoprotein analysis, Adv Lipid Res, 6, 1
- Amatruda, 1974, Type III hyperlipoproteinemia with mesangial foam cells in renal glomeruli, Arch Pathol, 98, 51
Cited by
Sorted by citations
Lipid abnormalities in renal disease
Appel, G. B. (1991) · Kidney International · doi:10.1038/ki.1991.22 · Cited by 278
Keane, W. F. (1994) · Kidney International · doi:10.1038/ki.1994.349 · Cited by 205
Lipid Abnormalities in the Nephrotic Syndrome: Causes, Consequences, and Treatment
Wheeler, D. C., & Bernard, D. B. (1994) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80994-2 · Cited by 186
Systemic and renal lipids in kidney disease development and progression
WAHL, P. W., Ducasa, G. M., & Fornoni, A. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00375.2015 · Cited by 147
Oikawa, S., Matsunaga, A., Saito, T., Sato, H., Seki, T., Hoshi, K., Hayasaka, K., Kotake, H., Midorikawa, H., Sekikawa, A., et al. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v85820 · Cited by 103
Self-citationImpact of Lipoprotein Glomerulopathy on the Relationship Between Lipids and Renal Diseases
Saito, T., Matsunaga, A., & Oikawa, S. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.10.017 · Cited by 96
Self-citationA novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy
Matsunaga, A., Sasaki, J., Komatsu, T., Kanatsu, K., Tsuji, E., Moriyama, K., Koga, T., Arakawa, K., Oikawa, S., Saito, T., et al. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00572.x · Cited by 91
Self-citationThe role of lipids in nephrosclerosis and glomerulosclerosis
Gröne, E. F., Walli, A. K., Gröne, H., Miller, B., & Seidel, D. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90136-8 · Cited by 91
Apolipoprotein E–related glomerular disorders
Saito, T., Matsunaga, A., Fukunaga, M., Nagahama, K., Hara, S., & Muso, E. (2020) · Kidney International · doi:10.1016/j.kint.2019.10.031 · Cited by 77
Self-citationKasiske, B. L., O’Donnell, M. P., Cowardin, W., & Keane, W. F. (1990) · Hypertension · doi:10.1161/01.hyp.15.5.443 · Cited by 67
Abnormal Lipoprotein and Apolipoprotein Pattern in Lipoprotein Glomerulopathy
Oikawa, S., Suzuki, N., Sakuma, E., Saito, T., Namai, K., Kotake, H., Fujii, Y., & Toyota, T. (1991) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80649-4 · Cited by 60
Self-citationHu, Z., Huang, S., Wu, Y., Liu, Y., Liu, X., Su, D., Tao, Y., Fu, P., Zhang, X., Peng, Z., et al. (2014) · Kidney International · doi:10.1038/ki.2013.335 · Cited by 60
Ishigaki, Y., Oikawa, S., Suzuki, T., Usui, S., Magoori, K., Kim, D.-H., Suzuki, H., Sasaki, J., Sasano, H., Okazaki, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005906200 · Cited by 58
Self-citationGlomerular diseases: genetic causes and future therapeutics
Chiang, C., & Inagi, R. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.103 · Cited by 57
Appel, G. B., Radhakrishnan, J., & D’Agati, V. D. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10032-6 · Cited by 56
Apolipoprotein E2/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney
MIYATA, T., SUGIYAMA, S., NANGAKU, M., SUZUKI, D., URAGAMI, K.-I., INAGI, R., SAKAI, H., & KUROKAWA, K. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1071590 · Cited by 55
Konishi, K., Saruta, T., Kuramochi, S., Oikawa, S., Saito, T., Han, H., Matsunaga, A., & Sasaki, J. (1999) · Nephron · doi:10.1159/000045513 · Cited by 54
Self-citationA novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy
Ando, M., Sasaki, J., Hua, H., Matsunaga, A., Uchida, K., Jou, K., Oikawa, S., Saito, T., & Nihei, H. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00677.x · Cited by 53
Self-citationLipoprotein Glomerulopathy: A New Apolipoprotein E Mutation With Enhanced Glomerular Binding
Sam, R., Wu, H., Yue, L., Mazzone, T., Schwartz, M. M., Arruda, J. A. L., Dunea, G., & Singh, A. K. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.12.031 · Cited by 53
Hyperlipidemia in kidney disease: causes and consequences
Sahadevan, M., & Kasiske, B. L. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200205000-00009 · Cited by 52
Lipoprotein glomerulopathy: renal lipidosis induced by novel apolipoprotein E variants
Saito, T., Oikawa, S., Sato, H., & Sasaki, J. (1999) · Nephron · doi:10.1159/000045511 · Cited by 46
Self-citationArai, T., Yamashita, S., Yamane, M., Manabe, N., Matsuzaki, T., Kiriyama, K., Kanayama, Y., Himeno, S., & Matsuzawa, Y. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00194-1 · Cited by 43
Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy
Ieiri, N., Hotta, O., & Taguma, Y. (2003) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2003.50016 · Cited by 50
HOFFMANN, M. M., SCHARNAGL, H., PANAGIOTOU, E., BANGHARD, W. T., WIELAND, H., & MA[Combining Diaeresis]RZ, W. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v123524 · Cited by 42
A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy
Kinomura, M., Sugiyama, H., Saito, T., Matsunaga, A., Sada, K.-E., Kanzaki, M., Takazawa, Y., Maeshima, Y., Yanai, H., & Makino, H. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm675 · Cited by 40
Self-citationRussi, G., Furci, L., Leonelli, M., Magistroni, R., Romano, N., Rivasi, P., & Albertazzi, A. (2009) · Journal of Medical Case Reports · doi:10.1186/1752-1947-3-9311 · Cited by 39
A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy
Ogawa, T., Maruyama, K., Hattori, H., Arai, H., Kondoh, I., Egashira, T., Watanabe, T., Kobayashi, Y., & Morikawa, A. (2000) · Pediatric Nephrology · doi:10.1007/s004670050032 · Cited by 37
Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features
Saito, T., Oikawa, S., Sato, H., Sato, T., Ito, S., & Sasaki, J. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07110.x · Cited by 37
Self-citationLuo, B., Huang, F., Liu, Q., Li, X., Chen, W., Zhou, S.-F., & Yu, X. (2008) · American Journal of Nephrology · doi:10.1159/000111828 · Cited by 36
Tsimihodimos, V., & Elisaf, M. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328345ebb0 · Cited by 33
Matsunaga, A., & Saito, T. (2014) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0918-1 · Cited by 33
Self-citationTopics in lipoprotein glomerulopathy: an overview
Saito, T., Matsunaga, A., Ito, K., & Nakashima, H. (2014) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0887-4 · Cited by 33
Self-citationNovel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity
Sakatsume, M., Kadomura, M., Sakata, I., Imai, N., Kondo, D., Osawa, Y., Shimada, H., Ueno, M., Miida, T., Nishi, S., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0590051911.x · Cited by 46
Madden, B. J., Singh, R. D., Haas, M., Palma, L. M. P., Sharma, A., Vargas, M. J., Gross, L., Negron, V. C., Nate, T., Charlesworth, M. C., et al. (2024) · Kidney International · doi:10.1016/j.kint.2024.02.013 · Cited by 31
A Novel Mutation ApoE2 Kurashiki (R158P) in a Patient with Lipoprotein Glomerulopathy
Tokura, T., Itano, S., Kobayashi, S., Kuwabara, A., Fujimoto, S., Horike, H., Satoh, M., Komai, N., Tomita, N., Matsunaga, A., et al. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.8102 · Cited by 28
Self-citationMatsunaga, A., Furuyama, M., Hashimoto, T., Toyoda, K., Ogino, D., & Hayasaka, K. (2009) · Clinical and Experimental Nephrology · doi:10.1007/s10157-009-0207-1 · Cited by 28
Histiocytic and Nonhistiocytic Glomerular Lesions: Foam Cells and Their Mimickers
Kaur, A., & Sethi, S. M. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.07.040 · Cited by 27
The renal biopsy in the genomic era
Liapis, H., & Gaut, J. P. (2012) · Pediatric Nephrology · doi:10.1007/s00467-012-2356-9 · Cited by 27
Xin, Z., Zhihong, L., Shijun, L., Jinfeng, Z., Huiping, C., Caihong, Z., Daxi, J., & Leishi, L. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn555 · Cited by 27
A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy
Hagiwara, M., Yamagata, K., Matsunaga, T., Arakawa, Y., Usui, J., Shimizu, Y., Aita, K., Nagata, M., Koyama, A., Zhang, B., et al. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm735 · Cited by 27
Self-citationLong-term follow-up of a paediatric case of lipoprotein glomerulopathy
Koitabashi, Y., Ikoma, M., Miyahira, T., Fujita, R., Mio, H., Ishida, M., Shimizu, K., & Sakaguchi, H. (1990) · Pediatric Nephrology · doi:10.1007/bf00858822 · Cited by 26
Self-citationLipoprotein glomerulopathy: A new aspect of lipid induced glomerular injury
Saito, T., Satō, H., & Oikawa, S. (1995) · Nephrology · doi:10.1111/j.1440-1797.1995.tb00004.x · Cited by 26
Self-citationAn Updated Review and Meta Analysis of Lipoprotein Glomerulopathy
Li, M.-S., Li, Y., Liu, Y., Zhou, X.-J., & Zhang, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.905007 · Cited by 25
Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy
Saito, T., Ishigaki, Y., Oikawa, S., & Yamamoto, T. T. (2002) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00148-7 · Cited by 25
Self-citationKanamaru, Y., Nakao, A., Shirato, I., Okumura, K., Ogawa, H., Tomino, Y., & Ra, C. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000015615.14428.67 · Cited by 25
Kaneoka, H., Uesugi, N., Moriguchi, A., Hirose, S., Takayanagi, M., Yamaguchi, S., Shigematsu, Y., Yasuno, T., Sasatomi, Y., & Saito, T. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.12.006 · Cited by 25
Self-citationWu, H., Yang, Y., & Hu, Z. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.41996 · Cited by 24
Lipoprotein Glomerulopathy: First Report in a Chinese Male
Zhang, P., Matalon, R., Kaplan, L., Kumar, A., & Gallo, G. (1994) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)81066-3 · Cited by 37
Tramontano, D., D'Erasmo, L., Larouche, M., Brisson, D., Lauzière, A., Di Costanzo, A., Bini, S., Minicocci, I., Covino, S., Baratta, F., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119146 · Cited by 23
Lipoprotein glomerulopathy: a pediatric case report
Maruyama, K., Arai, H., Ogawa, T., Tomizawa, S., & Morikawa, A. (1997) · Pediatric Nephrology · doi:10.1007/s004670050264 · Cited by 23
A Case of Lipoprotein Glomerulopathy: Light and Electron Microscopic Observations of the Glomerulus
Shibata, T., Kaneko, N., Hara, Y., Saito, T., & Sakaguchi, H. (1990) · Acta Pathologica Japonica · doi:10.1111/j.1440-1827.1990.tb01586.x · Cited by 22
Self-citationIto, K., Nakashima, H., Watanabe, M., Ishimura, A., Miyahara, Y., Abe, Y., Yasuno, T., Ifuku, M., Sasatomi, Y., & Saito, T. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs329 · Cited by 21
Self-citationAbnormal lipid metabolism and renal disorders
Saito, T. (1997) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.181.321 · Cited by 35
Self-citationA founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy
Toyota, K., Hashimoto, T., Ogino, D., Matsunaga, A., Ito, M., Masakane, I., Degawa, N., Sato, H., Shirai, S., Umetsu, K., et al. (2013) · Journal of Human Genetics · doi:10.1038/jhg.2013.8 · Cited by 19
Self-citationArterial hypertension and hyperlipidemia as determinants of glomerulosclerosis
Gröne, H., Walli, A. K., & Gr�ne, E. F. (1993) · Journal of Molecular Medicine · doi:10.1007/bf00190332 · Cited by 19
Lipoprotein glomerulopathy may provide a key to unlock the puzzles of renal lipidosis
Saito, T., & Matsunaga, A. (2014) · Kidney International · doi:10.1038/ki.2013.404 · Cited by 18
Self-citationRole of apolipoprotein E variants in lipoprotein glomerulopathy and other renal lipidoses
Saito, T., Ishigaki, Y., Oikawa, S., & Yamamoto, T. T. (2001) · Clinical and Experimental Nephrology · doi:10.1007/s10157-001-8014-3 · Cited by 18
Self-citationA Case of Lipoprotein Glomerulopathy with apoE Chicago and apoE (Glu3Lys) Treated with Fenofibrate
Kodera, H., Mizutani, Y., Sugiyama, S., Miyata, T., Ehara, T., Matsunaga, A., & Saito, T. (2017) · Case Reports in Nephrology and Dialysis · doi:10.1159/000478902 · Cited by 17
Self-citationIshimura, A., Watanabe, M., Nakashima, H., Ito, K., Miyake, K., Mochizuki, S., Ishigaki, Y., & Saito, T. (2009) · Clinical and Experimental Nephrology · doi:10.1007/s10157-009-0195-1 · Cited by 17
Self-citationRheault, M. N., & Kashtan, C. E. (2015) · Springer eBooks · doi:10.1007/978-3-662-43596-0_79 · Cited by 17
Association of Apolipoprotein E Polymorphism with Lipoprotein Glomerulopathy
Yang, A. H., Ng, Y. Y., Tarng, D., Chen, J. Y., Shiao, M. S., & Kao, J. (1998) · The Nephron journals/Nephron journals · doi:10.1159/000044933 · Cited by 16
Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations
Yang, M., Weng, Q., Pan, X., Hussain, H. M. J., Yu, S., Xu, J., Yu, X., Liu, Y., Jin, Y., Zhang, C., et al. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1281 · Cited by 15
Karet, F. E., & Lifton, R. P. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v85840 · Cited by 15
Fukunaga, M., Nagahama, K., Aoki, M., Shimizu, A., Hara, S., Matsunaga, A., Muso, E., & Saito, T. (2018) · Case Reports in Nephrology and Dialysis · doi:10.1159/000487919 · Cited by 14
Self-citationImpact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features
Matsunaga, A., & Saito, T. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65393 · Cited by 14
Self-citationCambruzzi, E., & Pêgas, K. L. (2019) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2018-0148 · Cited by 14
Lipoprotein glomerulopathy: first report of 2 not consanguineous Italian men from the same town
Pasquariello, A., Pasquariello, G., Innocenti, M., Minnei, F., Funel, N., Lorusso, P., & Barsotti, G. (2011) · Journal of Nephrology · doi:10.5301/jn.2011.7772 · Cited by 14
A Rare Cause of Posttransplantation Nephrotic Syndrome
Foster, K., Matsunaga, A., Matalon, R., Saito, T., Gallo, G., D’Agati, V., & Stokes, M. B. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.08.048 · Cited by 14
Self-citationLipoprotein Glomerulopathy Associated with a Mutation in Apolipoprotein E
Magistroni, R., Bertolotti, M., Furci, L., Fano, R. A., Leonelli, M., Pisciotta, L., Pellegrini, E., Calabresi, L., Bertolini, S., & Calandra, S. (2013) · Clinical Medicine Insights: Case Reports · doi:10.4137/ccrep.s12209 · Cited by 13
Mourad, G., Cristol, J. P., Turc-Baron, C., & Djamali, A. (1997) · Transplantation Proceedings · doi:10.1016/s0041-1345(97)00409-0 · Cited by 14
Pathology of glomerular lipidosis
Sato, H., Takahashi, N., Sato, E., Kisu, K., Ito, S., & Saito, T. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0882-9 · Cited by 12
Self-citationScavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy
Miyahara, Y., Nishimura, S., Watanabe, M., Ito, K., Nakashima, H., & Saito, T. (2011) · Clinical and Experimental Nephrology · doi:10.1007/s10157-011-0554-6 · Cited by 12
Self-citationSerum cholesterol and risk of end-stage renal disease in a cohort of mass screening
Iseki, K., Ikemiya, Y., & Fukiyama, K. (1998) · Clinical and Experimental Nephrology · doi:10.1007/bf02480619 · Cited by 12
Lipoprotein glomerulopathy with a new apolipoprotein E phenotype
Komatsu, T., Kanatsu, K., Ochi, H., Kita, T., & Doi, T. (1995) · American Journal of Kidney Diseases · doi:10.1016/0272-6386(95)90581-2 · Cited by 12
Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol
Hamatani, H., Hiromura, K., Kobatake, K., Yoshida, H., Kobayashi, S., Yoneda, N., Kayakabe, K., Matsumoto, T., Kuroiwa, T., Ueki, K., et al. (2010) · Clinical and Experimental Nephrology · doi:10.1007/s10157-010-0333-9 · Cited by 11
Li, W., Wang, Y., Han, Z., Luo, C., Zhang, C., & Xiong, J. (2014) · Kidney and Blood Pressure Research · doi:10.1159/000355810 · Cited by 11
Boumendjel, R., Papari, M., & Gonzalez, M. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/134.2.279 · Cited by 11
Grünfeld, J., Chauveau, D., & Accent]vy, M. L. A. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000015235.57104.a1 · Cited by 9
A novel apolipoprotein E mutation (p.Arg150Cys) in a Chinese patient with lipoprotein glomerulopathy
Ku, M., Tao, C., Zhou, A.-A., Cheng, Y., & Wan, Q.-J. (2019) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000050 · Cited by 8
Lipoprotein Glomerulopathy and Its Pathogenesis
Saito, T., Oikawa, S., Sato, H., & Chiba, J. (1997) · Contributions to Nephrology · doi:10.1159/000059821 · Cited by 12
Self-citationXie, W., Xie, Y., Lin, Z., Xu, X., & Zhang, Y. (2019) · Diagnostic Pathology · doi:10.1186/s13000-019-0820-6 · Cited by 9
Lipoprotein glomerulopathy: a case report of a rare disease in a brazilian child
Pêgas, K. L., Rohde, R., Garcia, C. D., Bittencourt, V. D. B., Keitel, E., Poloni, J. A. T., & Cambruzzi, E. (2014) · Jornal Brasileiro de Nefrologia · doi:10.5935/0101-2800.20140015 · Cited by 8
Hirashima, H., Komiya, T., Toriu, N., Hara, S., Matsunaga, A., Saito, T., & Muso, E. (2018) · Clinical Nephrology – Case Studies · doi:10.5414/cncs109509 · Cited by 8
Self-citationMochizuki, S., Moriya, T., Naganuma, H., Narasaka, T., Ueno, Y., Sato, H., Sasano, H., & Saito, T. (2001) · Clinical and Experimental Nephrology · doi:10.1007/s10157-001-8020-5 · Cited by 8
Self-citationLipoprotein Glomerulopathy, First Case Report from Canada
Ting, J. A., McRae, S. A., Schwartz, D., Barbour, S. J., & Riazy, M. (2022) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s364890 · Cited by 7
Takasaki, S., Matsunaga, A., Joh, K., & Saito, T. (2018) · CEN Case Reports · doi:10.1007/s13730-018-0309-2 · Cited by 7
Self-citationSaito, T., & Matsunaga, A. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.10165 · Cited by 7
Self-citationA newborn infant with lipoprotein glomerulopathy associated with congenital nephrotic syndrome
Shimizu, M., Ohno, T., Kimoto, H., Hosono, S., & Nozawa, M. (2001) · Pediatrics International · doi:10.1046/j.1442-200x.2001.01344.x · Cited by 8
Qin, Y., Sun, X.-J., Hu, Y.-F., Jing, M., Yu, X.-J., Zhao, M.-H., & Tan, Y. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2332491 · Cited by 7
A case of lipoprotein glomerulopathy with thrombotic microangiopathy due to malignant hypertension
Wu, Y., Chen, X., Yang, Y., Wang, B., Liu, X., Tao, Y., Fu, P., & Hu, Z. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-53 · Cited by 7
Macrophage Infiltration into the Glomeruli in Lipoprotein Glomerulopathy
Takasaki, S., Maeda, K., Joh, K., Yamakage, S., Fukase, S., Takahashi, T., Suzuki, M., Matsunaga, A., & Saito, T. (2015) · Case Reports in Nephrology and Dialysis · doi:10.1159/000441715 · Cited by 7
Self-citationFive-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation
Usui, R., Takahashi, M., Nitta, K., & Koike, M. (2016) · CEN Case Reports · doi:10.1007/s13730-016-0214-5 · Cited by 7
Lipoprotein Glomerulopathy in a Hispanic Female: A Case Report and Literature Review
Majeed, N. K., McLaughlin, J., & Gonzalez, M. (2019) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358119859576 · Cited by 6
Pasquariello, A. (2014) · Journal of Genetic Disorders & Genetic Reports · doi:10.4172/2327-5790.1000113 · Cited by 6
Cheung, C. Y., Chan, A. O. K., Chan, G. P. T., Iu, H. Y. P., Shek, C. C., & Chau, K. (2014) · Clinical Kidney Journal · doi:10.1093/ckj/sfu058 · Cited by 6
Karube, M., Nakabayashi, K., Fujioka, Y., Yoshihara, K., Yamada, A., Matsunaga, A., & Saito, T. (2007) · Clinical and Experimental Nephrology · doi:10.1007/s10157-007-0469-4 · Cited by 6
Self-citationChronic Renal Failure: An Overview from a Pediatric Perspective
Saborío, P., Hahn, S.-H., Hisano, S., Latta, K., Scheinman, J. I., & Chan, J. C. M. (1998) · The Nephron journals/Nephron journals · doi:10.1159/000045157 · Cited by 6
Wang, R., Zhao, C., Chen, W., Liu, Z., & Xie, F. (2022) · Journal of Medical Case Reports · doi:10.1186/s13256-022-03302-0 · Cited by 5
Li, Y., Chen, J., Zou, Y., Wang, W., & Li, G. (2022) · Medicine · doi:10.1097/md.0000000000028718 · Cited by 5
Apolipoprotein E-associated Lipoprotein Glomerulo-tubulopathy
Tanimizu, H., Hara, R., Sekine, A., Inoue, N., Hasegawa, E., Tanaka, K., Kono, K., Kinowaki, K., Ohashi, K., Okubo, M., et al. (2023) · Internal Medicine · doi:10.2169/internalmedicine.0834-22 · Cited by 5
Self-citation
Metadata
- Authors
- Saito, T., Sato, H., Kudo, K.-I., Oikawa, S.-I., Shibata, T., Hara, Y., Yoshinaga, K., & Sakaguchi, H.
- Affiliations
- Tohoku University (JP)
- Corresponding author
- Saito, Takao
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 1989-02
- Volume
- 13
- Issue
- 2
- Pages
- 148-153
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W1964757582
- Semantic Scholar
- da403efad9eaea0bf6dbcbfdb6bf2659875fab39
- Cited by
- 148
- References
- 30
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 6 · 2017: 1 · 2016: 6 · 2015: 4 · 2014: 8 · 2013: 8 · 2012: 5
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Kidney Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- lipoprotein glomerulopathy, type III hyperlipoproteinemia, familial hypercholesterolemia, proteinuria, lipid metabolism disorders, renal biopsy histology
- MeSH terms
- Adult, Capillaries, Female, Humans, Hyperlipoproteinemias, Immunoglobulin G, Immunoenzyme Techniques, Kidney Diseases, Kidney Glomerulus, Lipoproteins, LDL, Middle Aged, Sclerosis, Thrombosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
